NASDAQ: EOLSEvolus Inc Stock
$13.47+0.19 (+1.43%)
Updated Mar 19, 2025
EOLS Price
$13.47
Fair Value Price
N/A
Market Cap
$856.51M
52 Week Low
$9.25
52 Week High
$17.82
P/E
-16.63x
P/B
155.11x
P/S
2.57x
PEG
N/A
Dividend Yield
N/A
Revenue
$266.27M
Earnings
-$50.42M
Gross Margin
68.5%
Operating Margin
-11.65%
Profit Margin
-18.9%
Debt to Equity
41.12
Operating Cash Flow
-$18M
Beta
1.07
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
EOLS Overview
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EOLS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
EOLS
Ranked#16 of 58
Ranked#16 of 58
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.28 | A | |
| $5.07 | A | |
| $6.68 | A |
Be the first to know about important EOLS news, forecast changes, insider trades & much more!
EOLS News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EOLS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EOLS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EOLS is poor value based on its book value relative to its share price (155.11x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.25x)
P/B vs Industry Valuation
EOLS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more EOLS due diligence checks available for Premium users.
Valuation
EOLS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-16.63x
Industry
11.23x
Market
31.13x
EOLS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
155.11x
Industry
2.25x
EOLS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EOLS's financial health
Profit margin
Revenue
$78.9M
Net Income
-$6.8M
Profit Margin
-8.6%
EOLS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
EOLS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$232.6M
Liabilities
$227.0M
Debt to equity
41.12
EOLS's short-term assets ($151.34M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EOLS's long-term liabilities ($164.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EOLS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
EOLS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$4.8M
Investing
-$1.4M
Financing
-$1.3M
EOLS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EOLS vs Pharmaceutical Stocks
Evolus Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.